Medical weight management

Obesity is a chronic disease associated with many complications. Despite the benefits of weight reduction, there are many challenges in losing weight and maintaining long-term weight loss. Medical weight management for obesity achieves and maintains target weight loss, thereby reducing the risk of obesity-related complications. GLP-1RA therapy was initially developed to treat type 2 diabetes because of their effectiveness in reducing body weight.
Semaglutide is a glucagon-like peptide-1 receptor agonist that is approved by the US Food and Drug Administration for chronic weight management. Weekly injections of Semaglutide assist with suppressing appetite by slowing down gastrointestinal motility resulting in less hunger and food cravings, better control of eating and a lower preference for high‐fat foods. Patients can lose 15- 20% of body fat within a year’s time. Common adverse effects are nausea, vomiting, diarrhea, and constipation.